Biogen Announces FDA Approves High Dose Regimen of SPINRAZA To Treat Spinal Muscular Atrophy - Biogen (NASDAQ:BIIB)
Published on March 30, 2026.
The FDA has approved a high dose of high-profile treatments for the treatment of spinal Muscular Atrophy, including the high-ranking dermatologist. The drug is also known for its effectiveness in the face of the disease. The company's new strategy is designed to combat the disease, which is causing significant disruption to the health of the population.
Related Articles
Bond blues hit Big Tech at the worst time
Big Tech faces significant debt and profit challenges due to massive capex investments, rising inflation, and a weak stock market.
Goldman says traders have Fed outlook wrong as oil surge drives rate-hike fears
Goldman Sachs warns investors to avoid underestimating the Federal Reserve's potential response to an oil-driven inflation shock, as market expectations shift dramatically amid rising oil prices and economic concerns.
Gold price per ounce on March 30, 2026
Gold prices rose 1.84% to $4,576.33 per ounce today, with recent gains offsetting declines of up to 13.31%, driven by inflation expectations and demand factors.